Share Name Share Symbol Market Type Share ISIN Share Description
Medica Group Plc LSE:MGP London Ordinary Share GB00BYV24996 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 157.00 20,522 09:21:18
Bid Price Offer Price High Price Low Price Open Price
157.50 162.50 157.00 157.00 157.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 46.54 9.59 7.12 22.1 192
Last Trade Time Trade Type Trade Size Trade Price Currency
09:47:47 O 312 159.25 GBX

Medica (MGP) Latest News

More Medica News
Medica Investors    Medica Takeover Rumours

Medica (MGP) Discussions and Chat

Medica Forums and Chat

Date Time Title Posts
16/4/202109:11Medica Group733
04/8/200913:33Mercury Group: Charts and Comment254
24/7/200815:11Mercury Group...A New Beginning.668
14/10/200517:59Mercury Group (Old Cater Barnard) A New Beginning254
16/4/200407:53Make My Day5

Add a New Thread

Medica (MGP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Medica trades in real-time

Medica (MGP) Top Chat Posts

Medica Daily Update: Medica Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker MGP. The last closing price for Medica was 157p.
Medica Group Plc has a 4 week average price of 146p and a 12 week average price of 110p.
The 1 year high share price is 162.50p while the 1 year low share price is currently 95p.
There are currently 122,390,760 shares in issue and the average daily traded volume is 742,609 shares. The market capitalisation of Medica Group Plc is £192,153,493.20.
mighunter: Good overview of the company - Interview with Stuart Quin CEO. Also see on BBC that NHS operation waiting lists just hit 4.7m, highest since 2007. MGP sorely needed in future. HTtps://
mighunter: Did anyone else notice/can give explanation to the near minute by minute buys today in MGP, at deal sizes averaging about 160 shares per trade? Near continual throughout the day, most unlike MGP normal trading pattern? Someone accumulating??
cockerhoop: If I owned a business with a 4 year orderbook I'd also demand a decent takeout multiple. Also contained within the acquisition RNS was a trading update - MGP look sure to be involved in post covid effort the reduce the massive elective procedure backlog. Capacity increased by 13%.
adamb1978: Helpful that the share price has run up nicely in the last few weeks given the placing to finance the acquisition!
jumpingjack2016: APAD, looking at the L2P announcement that seems to be about a slick way for them to gather and maintain all the regulatory documents they need from their doctors. They call it a partnership, but I agree it sounds like L2P just sold them a solution. I think MGP have over 400 doctors so presumably that's a lot of qualification certificates, appraisals and insurance documents etc to gather, maintain and refresh! Doctors don't like that sort of paperwork so if it is slick it may help with the recruitment and retention of doctors? The Sectra investment looks to be more substantial and sounds like a good move (switching from an old system to a new one, access to new AI tools etc), but just how much impact it will have is an unknown. They also have not said if it costs more or less than the current system. Interesting to watch this one now after the ride since IPO. I am hopeful that the new management team are making the right moves. Jack.
cockerhoop: I've been impressed with Stuart Quin in the couple of presentations i've viewed. What I don't understand yet is how the competition are able to operate successfully if they don't have the unique links into the NHS patient records and still able to apply pressure to MGP's margins. Bearing in mind the service MGP supply is generally an overflow product along with out of hours it seems the NHS backlog is going to provide really strong volumes post covid as the NHS looks to catch up. The only blackmark is the steady but shallow decline in gross margins. In an ideal world I'd prefer strong revenue growth with margins improving :-).
rivaldo: Liberum have this morning initiated coverage on MGP with a huge 66 page report, saying Buy with a 200p target.....
adamb1978: Hi Dave The challenge with looking at 2020 for MGP is that it was badly impacted by covid. That's going to have a huge impact on EPS and therefore the FY20 multiple will look high. Obviously if you believe that the covid-impacted FY20 represents the new-norm for MGP then it might be an appropriate basis for valuation, but in my view it will recover back to where it was pre-covid and continue the similar growth of pre-covid. Therefore, combined with the fact that you buy shares based on the future performance and cashflows, in my view FY20 results are largely irrelevant for valuing MGP. To answer your question, the broker forecasts which I see for them for FY20 show 3.6p EPS. Cheers, Adam
discodave45: Hi Adam,Thanks for your views on MGP, have been looking at similar growth potential for this sector and had a cursory look at MGP. However I felt it was priced about right even for the anticipated recovery in FY21 (PE 15), for FY20 it's siting on a rating of 50 (if my eps calc of about 2.5p is correct).All the best though as who knows how MGP will do in the next few years but not for me on valuation, good luck.
velod: This post in response to The BigShortFella’s request to me on another forum and is in reply to BSFella. Have no position in this share, nor intention to take one, but now it’s been brought to my attention might put it on a watchlist somewhere, out of sheer Nosey-Parker-interest on my part. Hi BSFella, Had the impression you were a micro-cap guy so surprised this is a quarter billion-pound MCap company. As a trend follower, no I would not buy this, at this juncture, based solely on the share price action alone. Momentum is iffy; albeit with a recent bull trend initiated, but it’s yet to be established if THIS TIME it will hold and build. Can’t understand why as the company as distinct from the share price appears to be a right little belter. Have access to the Piotroski F-Score and (if anyone hasn’t heard of that just Google) was gobsmacked at how MGP, the business, scored. It only goes and achieves top marks! Not only top marks but flying colours too, kind of top Marks! The highest a company can achieve is 9 - and MGP is rated a right royal gold standard 9. You can’t get higher. And that tells me this is one well-run, mean machine business. That being the case, what the hell’s happened to the share price momentum? I’m not built for fundamentals, but things like Return On Capital and ROE are excellent – no wonder it scored so highly on the F-Score. The business per se, independent of the share price rating, is a stonking belter! So why am I not interested? The share price soared until mid-summer. What happened at the height of summer? Because since then the share price has been unimpressive. Why has the market withdrawn its admiration by turning its back on the SP? And why that big retrace today, Friday? Perhaps I should read the posts below; somebody must have an idea. Why has the market withdrawn its initial embrace? Is it the PE ratio? Does the market think the current PE ratio is unworthy and is holding back? It is above the market average but not that much, (Edit, Upon reflection, well - yes that much. It is a 'fair bit' above the average). Unless I trawled through analysts reports something about this share price level, irks the market. Trendlines: It is currently on a little bull rally, but it’s been on and off all summer like that and looks disappointing to me. I, personally don’t trust the share price so wouldn’t take a long position. nor a short position because the share price has no real momentum for either strategy to be reliable. Until a clear trend breaks AND holds it’s a sit it out on the side-lines job for me with this one. Great company. Rubbish share price momentum.
Medica share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210423 09:05:16